Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020

作者：Fiona P. Havers, Carrie Reed, Travis Lim, Joel M. Montgomery, John D. Klena, Aron J. Hall, Alicia M. Fry, Deborah Cannon, Cheng‐Feng Chiang, Aridth Gibbons, Inna Krapiunaya, Maria Morales-Betoulle, Katherine Roguski, Mohammad Rasheed, Brandi Freeman, Sandra Lester, Lisa Mills, Darin S. Carroll, S. Michele Owen, Jeffrey A. Johnson, Vera Semenova, State Collaborator Group, Jarad Schiffer, Natalie J. Thornburg, Carina Blackmore, Debra Blog, Angela Dunn, Scott Lindquist, Scott Pritchard, Lynn Sosa, George Turabelidze, John Wiesman, Randall Williams · 发表于：medRxiv · 年份：2020 · DOI：10.1101/2020.06.25.20140384 · 被引用次数：72 · 研究领域：SARS-CoV-2 and COVID-19 Research、SARS-CoV-2 detection and testing、Respiratory viral infections research

Abstract Importance Reported cases of SARS-CoV-2 infection likely underestimate the prevalence of infection in affected communities. Large-scale seroprevalence studies provide better estimates of the proportion of the population previously infected. Objective To estimate prevalence of SARS-CoV-2 antibodies in convenience samples from several geographic sites in the United States. Design Serologic testing of convenience samples using residual sera obtained for routine clinical testing by two commercial laboratory companies. Setting Connecticut (CT), south Florida (FL), Missouri (MO), New York City metro region (NYC), Utah (UT), and Washington State’s (WA) Puget Sound region. Participants Persons of all ages with serum collected during intervals from March 23 through May 3, 2020. Exposure SARS-CoV-2 virus infection. Main outcomes and measures We estimated the presence of antibodies to SARS-CoV-2 spike protein using an ELISA assay. We standardized estimates to the site populations by age and sex. Estimates were adjusted for test performance characteristics (96.0% sensitivity and 99.3% specificity). We estimated the number of infections in each site by extrapolating seroprevalence to site populations. We compared estimated infections to number of reported COVID-19 cases as of last specimen collection date. Results We tested sera from 11,933 persons. Adjusted estimates of the proportion of persons seroreactive to the SARS-CoV-2 spike protein ranged from 1.13% (95% confidence inter...